度普利尤单抗注射液致关节疼痛与肌无力1例分析

doi:10.19803/j.1672-8629.20250622

摘要/Abstract

摘要： 目的探讨度普利尤单抗致关节疼痛、肌无力及发生机制,为临床安全用药提供参考。方法分析1例重度哮喘患者使用度普利尤单抗致关节疼痛、肌无力的病例,评价关节疼痛、肌无力与度普利尤单抗的关联性,通过检索国内外相关文献进行分析。结果经查阅药品说明书和文献,分析用药时间,排除其他联合用药,考虑度普利尤单抗致关节疼痛、肌无力为“很可能”,患者停用该药并支持治疗后,上述症状逐渐缓解。结论临床应警惕度普利尤单抗所致关节疼痛、肌无力,重启该药应权衡利弊,加强用药监护。

关键词: 度普利尤单抗注射液, 支气管哮喘, 关节疼痛, 肌无力, 药品不良反应

Abstract: Objective To investigate such adverse reactions as joint pain and muscle weakness induced by dupilumab, and to explore the possible mechanisms in order to provide a reference for safe use of the drug. Methods One case of a patient with severe asthma who developed joint pain and muscle weakness after using dupilumab was analyzed. The correlation of these adverse events with dupilumab was studied. Furthermore, related literature was reviewed and summarized. Results After the drug instructions and literature were reviewed and the time of administration was analyzed, other combination drugs were excluded. The correlation between dupilumab and the adverse reactions of joint pain and muscle weakness was determined as “probable”. These symptoms gradually improved after drug discontinuation and supportive treatment. Conclusion Clinicians should be alert to the adverse reactions of joint pain and muscle weakness associated with dupilumab. When treatment with this drug is restarted, the risks and benefits should be weighed and monitored.

Key words: Dupilumab Injection, Bronchial Asthma, Joint Pain, Muscle Weakness, Adverse Drug Reaction

中图分类号:

张琴, 郑晓媛. 度普利尤单抗注射液致关节疼痛与肌无力1例分析[J]. 中国药物警戒, 2026, 23(5): 581-584.

ZHANG Qin, ZHENG Xiaoyuan. One Case of Joint Pain and Muscle Weakness Caused by Dupilumab Injection[J]. Chinese Journal of Pharmacovigilance, 2026, 23(5): 581-584.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20250622

https://zgywjj.magtechjournal.com/CN/Y2026/V23/I5/581

参考文献

[1] Respiratory Disease Branch of Chinese Medical Association. Guidelines for the Prevention and Treatment of Bronchial Asthma (2024 Edition)[J]. Chinese Journal of Tuberculosis and Respiratory Diseases(中华结核和呼吸杂志), 2025, 48(3):208-248.
[2] Chronic Airway Disease Professional Committee of China Medical Education Association. Chinese Expert Consensus on Diagnosis and Management of Severe Asthma(2024)[J]. National Medical Journal of China(中华医学杂志), 2024, 104(20):1759-1787.
[3] BRUSSELLE GG, KOPPELMAN GH.Biologic Therapies for Severe Asthma[J]. N EngI J Med, 2022, 386(2):157-171.
[4] BACHARIER LB, PAVORD ID, MASPERO JF, et al.Blood Eosinophils and Fractional Exhaled Nitric Oxide Are Prognostic and Predictive Biomarkers in Childhood Asthma[J]. J Allergy Clin Immunol, 2024, 154(1):101-110.
[5] LIEBERMAN JA, CHU DK, AHMED T, et al.A Systematic Review and Expert Delphi Consensus Recommendation on the Use of Vaccines in Patients Receiving Dupilumab:a Position Paper of the American College of Allergy, Asthma and Immunology[J]. Ann Allergy Asthma Immunol, 2024, 133(3):286-294.
[6] CASTRO M, PAPI A, PORSBJERG C, et al.Effect of Dupilumab on Exhaled Nitric Oxide, Mucus Plugs, and Functional Respiratory Imaging in Patients with Type 2 Asthma (VESTIGE):a Randomised, Double-Blind, Placebo-Controlled, Phase 4 Trial[J]. Lancet Respir Med, 2025, 13(3):208-220.
[7] BRIDGEWOOD C, WITTMANN M, MACLEOD T, et al.T Helper 2 IL-4/IL-13 Dual Blockade with Dupilumab Is Linked to Some Emergent T Helper 17-Type Diseases, Including Seronegative Arthritis and Enthesitis/Enthesopathy, but Not to Humoral Autoimmune Diseases[J]. J Invest Dermatol, 2022, 142(10):2660-2667.
[8] CHRÉTIEN B, DOLLADILLE C, ALEXANDRE J, et al. Dupilumab-associated Arthralgia:an Observational Retrospective Study in VigiBase[J]. Br J Dermatol, 2021, 185(2):464-465.
[9] SEE TOW HX, YEW YW.Joint Pain and Inflammatory Arthropathy after Dupilumab Use in Atopic Dermatitis:a Systematic Review and Meta-Analysis[J/OL]. Dermatitis,(2025-05-28)[2025-05-29]. https://doi:10.1089/derm.2025.0038.
[10] ARAKAWA N, INOUE T, TANJI T, et al.Development of Arthralgia during Treatment with Dupilumab in a Patient with Atopic Dermatitis[J]. J Dermatol, 2021, 48(8):e397-e398.
[11] SCHNEEWEISS MC, WYSS R, SCHNEEWEISS S, et al.Joint Pain in Patients with Atopic Dermatitis Receiving Treatment with Dupilumab:a US Nationwide Cohort Study[J]. J Am Acad Dermatol, 2024, 90(1):134-137.
[12] RAIMONDO A, GUGLIELMI G, MARINO C, et al.Acute Spondy-loarthritis Developing during Successful Treatment with Dupilumab for Severe Atopic Dermatitis[J]. Clin Exp Dermatol, 2022, 47(3):592-593.
[13] STEFANO LD, BOBBIO-PALLAVICINI F, MONTECUCCO C, et al.Dupilumab-Induced Enthesoarthritis and Refractory Atopic Dermatitis Successfully Treated with Baricitinib[J]. Rheumatology (Oxford), 2022, 61(3):e64-e66.
[14] HUGHES CD, NATHAN J, MATHEW L, et al.Characterization of a Musculo Skeletal Syndrome of Enthesitis and Arthritis in Patients with Atopic Dermatitis Treated with Dupilumab, Aninterleukin-4/13 Inhibitor[J]. Arthritis Rheumatol, 2023, 75(10):1793-1797.
[15] National Center for Adverse Drug Reaction Monitoring. Guideline for the Use of Adverse Drug Reaction Terminology[M]. Beijing:National Center for Adverse Drug Reaction Monitoring(国家药品不良反应监测中心), 2016.
[16] DE WIJS LEM, VAN DER WAA JD , DE JONG PHP, et al. Acute Arthritis and Arthralgia as an Adverse Drug Reaction to Dupilumab[J]. Clin Exp Dermatol, 2020, 45(2):262-263.
[17] DONG C, FU T, JI J, et al.The Role of Interleukin-4 in Rheumatic Diseases[J]. Clin Exp Pharmacol Physiol, 2018, 45(8):747-754.
[18] GUENOVA E, SKABYTSKA Y, HOETZENECKER W, et al.IL-4 Abrogates T(H) 17 Cell-Mediated Inflammation by Selective Silencing of IL-23 in Antigen-Presenting Cells[J]. Proc Natl Acad Sci USA, 2015, 112(7):2163-2168.
[19] LU D, LIU LQ, QUE WJ, et al. Hypothalamic Kisspeptin Alleviates Myasthenia Gravis by Regulating Th1/Th17/Treg Balance through Inhibition of NF-κB Signaling Pathway[J]. J Neuroinflammation, 2025, 16, 22(1):158.
[20] SONG J, XI JY, YU WB, et al.Inhibition of ROCK Activity Regulates the Balance of Th1, Th17 and Treg Cells in Myasthenia Gravis Clin Immunol[J]. Clin Immunol, 2019, 203:142-153.
[21] WU B, XU YJ, BAN YJ, et al.Correlation between the Intestinal Microflora and Peripheral Blood Th1/Th2 Balance in Hypothyroidism during the First Half of Pregnancy[J]. Front Cell Infect Microbiol, 2023, 13:1159238.
[22] ZHANG CC, XU YJ, ZHANG M, et al.An Exploratory Study on the Metagenomic and Proteomic Characterization of Hypothyroidism in the First Half of Pregnancy and Correlation with Th1/Th2 Balance[J]. Front Immunol, 2025, 16:1500866.
[23] WANG CM, CHEN YJ, YANG BC, et al.Supplementation with Active Vitamin D₃ Ameliorates Experimental Autoimmune Thyroiditis in Mice by Modulating the Differentiation and Functionality of Intrathyroidal T-Cell Subsets[J]. Front Immunol, 2025, 16:1528707.